DAX6.050-3,4%  Dow12.119-2,2%  Euro1,24320,6% 
ESt502.069-2,4%  Nas2.748-2,8%  Öl98,82-2,8% 
TDax730,9-2,7%  Nikkei8.440-1,2%  Gold1.6264,2% 
Home > Aktien > Acorda Therapeutics, Aktie > Nachrichten zu Acorda Therapeutics,

Acorda Therapeutics, Aktie [WKN: A0BK80 / ISIN: US00484M1062]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyHome
OrderbuchRealtime StuttgartRSS FeedAnalyseim ForumFondsSenden
HistorischRealtime PushmyNews neu IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Acorda Therapeutics, Inc.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Acorda Therapeutics, Inc.

20.05.11Biogen hofft auf baldige Vermarktung von Fampyra in Europa
22.03.10Acorda Therapeutics Announces Filing of Patent Extension Applications for AMPYRA™ (dalfampridine)
02.03.10Acorda Therapeutics to Present at the Cowen and Company 30th Annual Health Care Conference
01.03.10Acorda Therapeutics Announces Availability of AMPYRA™ (dalfampridine)
25.02.10Acorda Therapeutics to Participate in Panel at the RBC Capital Markets Healthcare Conference
23.02.10Acorda Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
22.02.10Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
17.02.10Acorda Therapeutics to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on February 23, 2010
03.02.10Acorda Therapeutics to Present at the 12th Annual BIO CEO & Investor Conference
03.02.10Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA™ (dalfampridine)
25.01.10Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
22.01.10Acorda Therapeutics Announces FDA Approval of AMPYRA™ (dalfampridine) to Improve Walking in People with Multiple Sclerosis – Demonstrated by Increases in Walking Speed
04.01.10Acorda Therapeutics to Present at the 28th Annual JPMorgan Healthcare Conference
08.12.09Acorda Therapeutics to Present at the 2009 Deutsche Bank Biotech Boston Confab
24.11.09Acorda Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
16.11.09Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
03.11.09Acorda Therapeutics Reports Third Quarter 2009 Financial Results
27.10.09Acorda Therapeutics to Host Conference Call to Report Third Quarter 2009 Financial Results on November 3, 2009
22.10.09Acorda Therapeutics Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010
14.10.09Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
14.10.09Acorda Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Review Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
09.10.09Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
15.09.09Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies
10.09.09Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study
25.08.09Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS
05.08.09Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development
04.08.09Acorda Therapeutics Reports Second Quarter 2009 Financial Results
28.07.09Acorda Therapeutics to Host Conference Call to Report Second Quarter 2009 Financial Results on August 4, 2009
01.07.09Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
08.06.09Acorda Therapeutics Announces Eligibility of Fampridine-SR for Centralized Review in Europe
06.05.09Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing
06.05.09Acorda Therapeutics Reports First Quarter 2009 Financial Results
29.04.09Study Highlights Economic Impact of Early Mobility Impairment in People with Multiple Sclerosis
29.04.09Acorda Therapeutics to Host Conference Call to Report First Quarter 2009 Financial Results on May 6, 2009
23.04.09Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
16.04.09Acorda Therapeutics to Present at the New York Biotechnology Association 18th Annual Meeting
10.04.09Acorda Therapeutics Names Anthony Caggiano Vice President, Preclinical Development
31.03.09Acorda Therapeutics Receives Refuse to File Letter from FDA on Fampridine-SR NDA
10.03.09Acorda Therapeutics to Present at the Cowen and Company 29th Annual Health Care Conference
26.02.09Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis

Anzeige

ANZEIGE

Seite: 123
Wie bewerten Sie diese Seite?
schlecht sehr gut
Problem mit dieser Seite?
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon